NCT07129252View on ClinicalTrials.gov

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2029

Conditions
SST2-positive Neuroendocrine NeoplasmsNeuroendocrine TumorsNeuroendocrine Neoplasm
Interventions
DRUG

CRN09682

Study drug CRN09682 intravenously

Sponsors
All Listed Sponsors
lead

Crinetics Pharmaceuticals Inc.

INDUSTRY

NCT07129252 - A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | Biotech Hunter | Biotech Hunter